S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Biden To Unleash "Choke Point" Operation On America? (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Biden To Unleash "Choke Point" Operation On America? (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Biden To Unleash "Choke Point" Operation On America? (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Biden To Unleash "Choke Point" Operation On America? (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Biden To Unleash "Choke Point" Operation On America? (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Biden To Unleash "Choke Point" Operation On America? (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Biden To Unleash "Choke Point" Operation On America? (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Biden To Unleash "Choke Point" Operation On America? (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NASDAQ:CRVS

Corvus Pharmaceuticals - CRVS Competitors

$0.91
+0.12 (+15.19%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.79
$0.93
50-Day Range
$0.65
$0.91
52-Week Range
$0.61
$2.11
Volume
500,629 shs
Average Volume
135,214 shs
Market Capitalization
$42.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

CRVS vs. CRBP, ORGS, TXMD, PPBT, YMTX, ELDN, CKPT, LPTX, RNXT, and SLS

Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Corbus Pharmaceuticals (CRBP), Orgenesis (ORGS), TherapeuticsMD (TXMD), Purple Biotech (PPBT), Yumanity Therapeutics (YMTX), Eledon Pharmaceuticals (ELDN), Checkpoint Therapeutics (CKPT), Leap Therapeutics (LPTX), RenovoRx (RNXT), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical preparations" industry.

Corvus Pharmaceuticals vs.

Corvus Pharmaceuticals (NASDAQ:CRVS) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, community ranking, analyst recommendations, valuation, risk and profitability.

Corvus Pharmaceuticals' return on equity of -56.80% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corvus Pharmaceuticals N/A -56.80% -48.25%
Corbus Pharmaceuticals N/A -80.51% -46.99%

Corvus Pharmaceuticals presently has a consensus target price of $3.17, suggesting a potential upside of 247.99%. Corbus Pharmaceuticals has a consensus target price of $3.00, suggesting a potential downside of 58.73%. Given Corvus Pharmaceuticals' higher probable upside, research analysts plainly believe Corvus Pharmaceuticals is more favorable than Corbus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Corbus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

47.5% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.7% of Corbus Pharmaceuticals shares are owned by institutional investors. 29.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 8.2% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Corbus Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corvus PharmaceuticalsN/AN/A-$43.24 million-$0.89-1.02
Corbus Pharmaceuticals$880 thousand34.45-$42.35 million-$10.42-0.70

Corbus Pharmaceuticals received 143 more outperform votes than Corvus Pharmaceuticals when rated by MarketBeat users. Likewise, 68.72% of users gave Corbus Pharmaceuticals an outperform vote while only 63.86% of users gave Corvus Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Corvus PharmaceuticalsOutperform Votes
281
63.86%
Underperform Votes
159
36.14%
Corbus PharmaceuticalsOutperform Votes
424
68.72%
Underperform Votes
193
31.28%

In the previous week, Corvus Pharmaceuticals had 8 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 8 mentions for Corvus Pharmaceuticals and 0 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.89 beat Corvus Pharmaceuticals' score of 0.26 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Corvus Pharmaceuticals Neutral
Corbus Pharmaceuticals Very Positive

Corvus Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.

Summary

Corbus Pharmaceuticals beats Corvus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRVS vs. The Competition

MetricCorvus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$42.38M$5.69B$4.46B$6.05B
Dividend YieldN/A2.64%2.42%5.45%
P/E Ratio-1.024.5179.5212.43
Price / SalesN/A284.223,588.8670.98
Price / CashN/A18.0728.9367.28
Price / Book0.444.294.615.04
Net Income-$43.24M$186.77M$115.07M$191.86M
7 Day Performance33.84%1.88%1.28%2.43%
1 Month Performance26.37%-7.91%-5.98%-4.59%
1 Year Performance-48.59%-10.89%-14.70%-16.31%

Corvus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRBP
Corbus Pharmaceuticals
1.6987 of 5 stars
$8.05
+8.1%
$3.00
-62.7%
+1,267.8%$33.57M$880,000.00-0.7741
ORGS
Orgenesis
2.08 of 5 stars
$1.23
-6.1%
$6.00
+387.8%
-66.0%$33.81M$36.03M-2.51111Short Interest ↓
Gap Up
TXMD
TherapeuticsMD
0.9266 of 5 stars
$3.54
+1.4%
N/A-80.3%$33.35M$86.95M-2.48416
PPBT
Purple Biotech
1.8877 of 5 stars
$1.79
+1.7%
$9.00
+402.8%
-54.5%$33.08M$1M-1.4819
YMTX
Yumanity Therapeutics
0 of 5 stars
$3.18
+2.3%
N/A+120.7%$34.52M$4.84M-1.0640Gap Up
ELDN
Eledon Pharmaceuticals
2.1819 of 5 stars
$2.37
+0.9%
$22.00
+828.3%
-40.1%$32.61MN/A-0.8912News Coverage
CKPT
Checkpoint Therapeutics
1.9999 of 5 stars
$3.49
-8.6%
$23.50
+573.4%
+27.1%$32.46M$270,000.00-0.4014Short Interest ↑
News Coverage
Gap Down
High Trading Volume
LPTX
Leap Therapeutics
1.7082 of 5 stars
$0.33
+6.5%
$2.80
+756.0%
-80.6%$32.39M$1.50M-0.6836Earnings Report
Short Interest ↑
Analyst Revision
News Coverage
RNXT
RenovoRx
1.0041 of 5 stars
$3.90
+28.7%
N/A+18.9%$35.37MN/A-3.5810Short Interest ↑
News Coverage
High Trading Volume
SLS
SELLAS Life Sciences Group
2.1057 of 5 stars
$1.25
+5.9%
$7.00
+460.0%
-78.6%$35.38M$1M-0.567Positive News
This page (NASDAQ:CRVS) was last updated on 4/1/2023 by MarketBeat.com Staff